Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
09 nov 2010 - 07:37
Statutaire naam
Crucell N.V.
Titel
Crucell Reports Third Quarter 2010 Results
Bericht
One-time inventory provision for Quinvaxem® stock of €22.8 million.
Total revenues and other operating income of €89.5 million compared to
€94.3 million in the same period in 2009.
Operating loss of €31.1 million compared to operating profit of
€15.5 million in Q3 2009. Net loss of €27.0 million compared to net profit of €10.0 million in Q3 2009 due to write-downs of Quinvaxem® inventory.
Undiluted EPS of minus €0.33 compared to €0.15 in the same quarter of 2009.
Change of 2010 guidance: total revenues and other operating income for the full year expected to be in-line with 2009 levels. Due to the one-time provision, operating loss for the year expected to be €20-25 million.
Datum laatste update: 12 februari 2025